Protease Inhibitor That May Aid In Diabetic Retinopathy Treatment Described By Researchers
24 Jan 2009
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, have announced that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes. The study, which was partly funded by the Read the rest of this entry »